Literature DB >> 11460008

In vitro interaction of C1-inhibitor with thrombin.

M Cugno1, I Bos, Y Lubbers, C E Hack, A Agostoni.   

Abstract

Previous observations of increased generation of thrombin during acute attacks of angioedema in plasma of patients with C1-inhibitor (C1-INH) deficiency prompted us to evaluate the interaction of C1-INH with thrombin in both purified systems and human plasma. For this purpose, we used several methods: (1) sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting analysis; (2) enzyme-linked immunosorbent assays to measure complexes between C1-INH and thrombin and inactivated C1-INH; and (3) kinetic studies using a chromogenic assay. We found that the interaction of purified C1-INH with thrombin is associated with the formation of bimolecular complexes of molecular weight (Mr) 130 000 and 120 000 as well as with the appearance of a cleaved form of C1-INH of Mr 97 000. The kinetic studies of inhibition of thrombin by C1-INH showed an average second-order rate constant of 19/s per mol/l, which was significantly increased in the presence of heparin. The addition of thrombin to human plasma was not associated with detectable C1-INH-thrombin complex formation or with cleavage of C1-INH. In conclusion, our data demonstrate that C1-INH upon interaction with thrombin, in part, forms enzyme-inhibitor complexes and, in part, is cleaved. The low second-order rate constant and the lack of a significant interaction in plasma suggest that the inhibition of thrombin by C1-INH has a minor role in circulating blood; however, its role might be important at the endothelial surface, where high concentrations of glycosaminoglycans occur.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11460008     DOI: 10.1097/00001721-200106000-00005

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  15 in total

1.  Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

Authors:  Angelo Agostoni; Emel Aygören-Pürsün; Karen E Binkley; Alvaro Blanch; Konrad Bork; Laurence Bouillet; Christoph Bucher; Anthony J Castaldo; Marco Cicardi; Alvin E Davis; Caterina De Carolis; Christian Drouet; Christiane Duponchel; Henriette Farkas; Kálmán Fáy; Béla Fekete; Bettina Fischer; Luigi Fontana; George Füst; Roberto Giacomelli; Albrecht Gröner; C Erik Hack; George Harmat; John Jakenfelds; Mathias Juers; Lajos Kalmár; Pál N Kaposi; István Karádi; Arianna Kitzinger; Tímea Kollár; Wolfhart Kreuz; Peter Lakatos; Hilary J Longhurst; Margarita Lopez-Trascasa; Inmaculada Martinez-Saguer; Nicole Monnier; István Nagy; Eva Németh; Erik Waage Nielsen; Jan H Nuijens; Caroline O'grady; Emanuela Pappalardo; Vincenzo Penna; Carlo Perricone; Roberto Perricone; Ursula Rauch; Olga Roche; Eva Rusicke; Peter J Späth; George Szendei; Edit Takács; Attila Tordai; Lennart Truedsson; Lilian Varga; Beáta Visy; Kayla Williams; Andrea Zanichelli; Lorenza Zingale
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

2.  New insight into the effects of heparinoids on complement inhibition by C1-inhibitor.

Authors:  F Poppelaars; J Damman; E L de Vrij; J G M Burgerhof; J Saye; M R Daha; H G Leuvenink; M E Uknis; M A J Seelen
Journal:  Clin Exp Immunol       Date:  2016-04-13       Impact factor: 4.330

3.  Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency.

Authors:  M van Geffen; M Cugno; P Lap; A Loof; M Cicardi; W van Heerde
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

Review 4.  Biological activities of C1 inhibitor.

Authors:  Alvin E Davis; Pedro Mejia; Fengxin Lu
Journal:  Mol Immunol       Date:  2008-07-31       Impact factor: 4.407

Review 5.  C1 inhibitor: molecular and clinical aspects.

Authors:  Marco Cicardi; Lorenza Zingale; Andrea Zanichelli; Emanuela Pappalardo; Benedetta Cicardi
Journal:  Springer Semin Immunopathol       Date:  2005-11-11

6.  Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot.

Authors:  Krishana C Gulla; Kshitij Gupta; Anders Krarup; Peter Gal; Wilhelm J Schwaeble; Robert B Sim; C David O'Connor; Krishnan Hajela
Journal:  Immunology       Date:  2009-12-02       Impact factor: 7.397

7.  Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema.

Authors:  Colm Farrell; Siobhan Hayes; Anurag Relan; Edwin S van Amersfoort; Rienk Pijpstra; C Erik Hack
Journal:  Br J Clin Pharmacol       Date:  2013-12       Impact factor: 4.335

Review 8.  Innate networking: Thrombotic microangiopathy, the activation of coagulation and complement in the sensitized kidney transplant recipient.

Authors:  Miriam Manook; Jean Kwun; Steven Sacks; Anthony Dorling; Nizam Mamode; Stuart Knechtle
Journal:  Transplant Rev (Orlando)       Date:  2018-02-10       Impact factor: 3.943

Review 9.  Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review.

Authors:  Alexander Fletcher-Sandersjöö; Bo-Michael Bellander
Journal:  Thromb Res       Date:  2020-06-18       Impact factor: 3.944

10.  Inhibition of plasma kallikrein by a highly specific active site blocking antibody.

Authors:  Jon A Kenniston; Ryan R Faucette; Diana Martik; Stephen R Comeau; Allison P Lindberg; Kris J Kopacz; Gregory P Conley; Jie Chen; Malini Viswanathan; Niksa Kastrapeli; Janja Cosic; Shauna Mason; Mike DiLeo; Jan Abendroth; Petr Kuzmic; Robert C Ladner; Thomas E Edwards; Christopher TenHoor; Burt A Adelman; Andrew E Nixon; Daniel J Sexton
Journal:  J Biol Chem       Date:  2014-06-26       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.